Tvardi Therapeutics (LTS:0HTC) Total Equity: £10.88 Mil (As of Mar. 2026)


What is Tvardi Therapeutics Total Equity?

Tvardi Therapeutics LTS:0HTC 12 Total Equity is £10.88 Mil as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Tvardi Therapeutics's total equity for the quarter that ended in Mar. 2026 was £10.88 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Tvardi Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Total Equity Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Equity
-36.99 -49.03 -72.09 15.65

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -6.25 24.27 20.62 15.65 10.88

Tvardi Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Tvardi Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=23.959-8.312
=15.65

Tvardi Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=19.363-8.484
=10.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of £10.88 Mil mean?
Tvardi Therapeutics (LTS:0HTC) has a Total Equity of £10.88 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Tvardi Therapeutics and its competitors.
Is Tvardi Therapeutics' Total Equity too high?
Tvardi Therapeutics' current Total Equity is £10.88 Mil. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Total Equity compare to HOWL and TPST?
Tvardi Therapeutics' Total Equity of £10.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Total Equity is £10.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Total Equity of £10.88 Mil. The current Total Equity is £10.88 Mil. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Total Equity is £10.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.